We work with clients, who range from Top 5 Pharma companies to SMEs, to develop and execute innovative regulatory strategies from early product development to post-licensing activities for medicines and medical devices.
We pride ourselves on our understanding of clients’ needs and our flexible, creative and pragmatic approach puts our clients and the patients they serve at the centre of everything we do.
GreyRigge Associates is a global biotech partner delivering consultancy, management expertise and training across the entire product development journey. Our extensive biopharmaceutical industry experience and pragmatic, agile approach enables transformational success by accelerating our clients’ medicines to market.
IDEA is passionate about getting innovative products to patients with unmet needs and we particularly enjoy putting our full weight of innovative thinking and regulatory expertise behind innovative medicine.
Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry. We are adept at solving complex issues associated with medicinal product development and offer strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory. Our industry experience is demonstrable, having been involved in over 1,000 development programmes in the US and Europe over the last twenty years. As is our scientific excellence, with a team that includes ex-regulators, high-calibre academics and clinician scientists. Our technical regulatory expertise spans the entire product development spectrum from pre-clinical to marketing authorisation.
The imminent expiration of patents for major pharmaceutical drugs, known as the "patent cliff," not only opens the market for lower-priced generics but also presents a prime opportunity for biotech companies to secure valuable partnerships with pharma as they seek to revitalise their portfolios.
